Tissue-type plasminogen activator activity in morphologically normal tissues adjacent to gastrointestinal carcinomas is associated with the degree of tumor progression

Scicolone, Gabriel; Sánchez, Viviana; Vauthay, Liliana; Fuentes, Federico; Scicolone, Alejandro; Scicolone, Lorenzo; Rapacioli, Melina; Flores, Verónica

doi:10.1007/s00432-005-0066-4

Cited by 3 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, Vidal et al showed that the preoperative serum uPA levels in gastric cancer patients were similar to those in the control subjects . High expression of uPAR, uPA, and PAI‐1 was observed in gastric tumors compared to normal tissues . Further, the expression of uPA and uPAR in gastric cancer was correlated to poor outcome .…”

Section: Clinical Relevance Of Components Of Upa System In Human Cancersmentioning

confidence: 99%

Involvement of Urokinase‐Type Plasminogen Activator System in Cancer: An Overview

Mekkawy

Pourgholami

Morris

2014

Medicinal Research Reviews

133

114

View full text Add to dashboard Cite

Currently, there are several studies supporting the role of urokinase-type plasminogen activator (uPA) system in cancer. The association of uPA to its receptor triggers the conversion of plasminogen into plasmin. This process is regulated by the uPA inhibitors (PAI-1 and PAI-2). Plasmin promotes degradation of basement membrane and extracellular matrix (ECM) components as well as activation of ECM latent matrix metalloproteases. Degradation and remodeling of the surrounding tissues is crucial in the early steps of tumor progression by facilitating expansion of the tumor mass, release of tumor growth factors, activation of cytokines as well as induction of tumor cell proliferation, migration, and invasion. Hence, many tumors showed a correlation between uPA system component levels and tumor aggressiveness and survival. Therefore, this review summarizes the structure of the uPA system, its contribution to cancer progression, and the clinical relevance of uPA family members in cancer diagnosis. In addition, the review evaluates the significance of uPA system in the development of cancer-targeted therapies.

show abstract

Section: Clinical Relevance Of Components Of Upa System In Human Cancersmentioning

confidence: 99%

Involvement of Urokinase‐Type Plasminogen Activator System in Cancer: An Overview

Mekkawy

Pourgholami

Morris

2014

Medicinal Research Reviews

133

114

View full text Add to dashboard Cite

show abstract

“…Tissue plasminogen activator (tPA) is the intra-vascular counterpart to uPA, involved in fibrin degradation to prevent blood clot formation [13]. However, tPA does not appear to play a significant role in the development of solid tumours [16].…”

Section: Introductionmentioning

confidence: 99%

Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma

Tincknell

Piper

Aghmesheh

et al. 2021

Cancers

View full text Add to dashboard Cite

Gastric and oesophageal cancers (GOCs) are lethal cancers which metastasise early and recur frequently, even after definitive surgery. The urokinase plasminogen activator system (uPAS) is strongly implicated in the invasion and metastasis of many aggressive tumours including GOCs. Urokinase plasminogen activator (uPA) interaction with its receptor, urokinase plasminogen activator receptor (uPAR), leads to proteolytic activation of plasminogen to plasmin, a broad-spectrum protease which enables tumour cell invasion and dissemination to distant sites. uPA, uPAR and the plasminogen activator inhibitor type 1 (PAI-1) are overexpressed in some GOCs. Accumulating evidence points to a causal role of activated receptor tyrosine kinase pathways enhancing uPAS expression in GOCs. Expression of these components are associated with poorer clinicopathological features and patient survival. Stromal cells, including tumour-associated macrophages and myofibroblasts, also express the key uPAS proteins, supporting the argument of stromal involvement in GOC progression and adverse effect on patient survival. uPAS proteins can be detected on circulating leucocytes, circulating tumour cells and within the serum; all have the potential to be developed into circulating biomarkers of GOC. Herein, we review the experimental and clinical evidence supporting uPAS expression as clinical biomarker in GOC, with the goal of developing targeted therapeutics against the uPAS.

show abstract

Good or bad: Paradox of plasminogen activator inhibitor 1 (PAI-1) in digestive system tumors

Wang¹,

Gu²,

Zhang³

et al. 2023

Cancer Letters

View full text Add to dashboard Cite

Tissue-type plasminogen activator activity in morphologically normal tissues adjacent to gastrointestinal carcinomas is associated with the degree of tumor progression

Abstract: "Morphologically normal tissues" adjacent to carcinomas present abnormal t-PA activity that is associated with the degree of tumor progression. Assaying of this activity could be useful as a predictive parameter.

Cited by 3 publications

References 41 publications

Involvement of Urokinase‐Type Plasminogen Activator System in Cancer: An Overview

Involvement of Urokinase‐Type Plasminogen Activator System in Cancer: An Overview

Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma

Good or bad: Paradox of plasminogen activator inhibitor 1 (PAI-1) in digestive system tumors

Contact Info

Product

Resources

About